Randomized Ph 2 Trial Of Paclitaxel/Carboplatin /Bevacizumab + PF-3512676 And P/C/B Alone In Advanced Nonsquamous NSCLC

• Status: Terminated
• Trial end date: 2008-05-01
• Target enrollment: 0
• Participant gender: All

Summary

To assess the efficacy and safety of PF-3512676 administered in combination with paclitaxel, carboplatin and bevacizumab as first-line treatment in patients with locally advanced or metastatic nonsquamous non-small cell lung cancer

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Pfizer
• Treatments: Albumin-Bound Paclitaxel; Bevacizumab; Carboplatin; Paclitaxel

Criteria

Inclusion Criteria:

• Advanced Stage IIIb with pleural effusion or Stage IV nonsquamous non-small cell lung cancer

• ECOG Performance Status 0-1

• Measurable disease per RECIST criteria

Exclusion Criteria:

• Squamous cell, small cell, or carcinoid lung cancer

• CNS metastasis

• Pre-existing autoimmune or antibody mediated disease

• Prior systemic treatment for NSCLC with chemo, immunotherapy, biologics, or investigation drugs